title: Modulatory role of garlicin in migration and invasion of intrahepatic cholangiocarcinoma via PI3K/AKT pathway.
abstract: Increasing evidences have indicated the role of garlicin in inhibiting the progression of various tumors including glioma, pulmonary carcinoma and pancreatic carcinoma, via mediating cell apoptosis or cell cycle. The regulatory effect and related molecular mechanism of garlicin in intrahepatic cholangiocarcinoma, however, remained unknown. This study thus aimed to investigate this scientific issue. HCCC-9810 cell line was treated with serially diluted garlicin, followed by cell proliferation assay using MTT approach. Transwell migration and invasion assays were further employed the regulatory effect of garlicin. The expression level of p-AKT and AKT proteins in tumor cells was quantified by Western blot. The growth of tumor cells was significantly inhibited by high concentration of garlicin (> 1.5 μM). Lower concentration of garlicin showed dose-dependent inhibition of tumor cell invasion and migration. After using specific agonist IGF-1 (50 ng/mL) of PI3K/AKT signaling pathway, such facilitating effects of garlicin were depressed (P < 0.05). Western blotting showed significantly decreased phosphorylation level of AKT after treated with gradient concentrations of garlicin, while leaving the total AKT protein level unchanged. Garlicin may inhibit the invasion and migration of intrahepatic cholangiocarcinoma cells via inhibiting PI3K/AKT signaling pathway.
authors.affiliation: Department of General Surgery, The First Affiliated Hospital of Medical University of Anhui Hefei 230022, Anhui, China.
authors.forename: Kun
authors.initials: K
authors.lastname: Xie
authors.affiliation: Department of General Surgery, The First Affiliated Hospital of Medical University of Anhui Hefei 230022, Anhui, China.
authors.forename: Jianze
authors.initials: J
authors.lastname: Nian
authors.affiliation: Department of General Surgery, The First Affiliated Hospital of Medical University of Anhui Hefei 230022, Anhui, China.
authors.forename: Xingyang
authors.initials: X
authors.lastname: Zhu
authors.affiliation: Department of General Surgery, The First Affiliated Hospital of Medical University of Anhui Hefei 230022, Anhui, China.
authors.forename: Xiaoping
authors.initials: X
authors.lastname: Geng
authors.affiliation: Department of General Surgery, The First Affiliated Hospital of Medical University of Anhui Hefei 230022, Anhui, China.
authors.forename: Fubao
authors.initials: F
authors.lastname: Liu
mesh_terms: D000498:Allyl Compounds / Q000494:pharmacology*; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology*; D001650:Bile Duct Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects*; D049109:Cell Proliferation / Q000187:drug effects; D018281:Cholangiocarcinoma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D004220:Disulfides / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009361:Neoplasm Invasiveness; D058539:Phosphatidylinositol 3-Kinase / Q000378:metabolism*; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010766:Phosphorylation; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D051057:Proto-Oncogene Proteins c-akt / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D000498:Allyl Compounds; D000972:Antineoplastic Agents, Phytogenic; D004220:Disulfides; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors; C028009:diallyl disulfide; D058539:Phosphatidylinositol 3-Kinase; D051057:Proto-Oncogene Proteins c-akt
keywords: Garlicin; PI3K/AKT signaling pathway; intrahepatic cholangiocarcinoma; tumor invasion; tumor migration
references.citation: Ann Med Health Sci Res. 2014 Nov;4(6):863-8
references.pmid: 25506477
references.citation: Neurochem Int. 2012 Oct;61(5):640-8
references.pmid: 22750272
references.citation: Cell Signal. 2013 Feb;25(2):447-56
references.pmid: 23123500
references.citation: Int J Clin Exp Pathol. 2014;7(11):8112-7
references.pmid: 25550859
references.citation: Br J Dermatol. 2002 Jan;146(1):69-73
references.pmid: 11841368
references.citation: Cancer Biol Med. 2012 Jun;9(2):90-8
references.pmid: 23691461
references.citation: Oncol Rep. 2012 Jul;28(1):41-8
references.pmid: 22552443
references.citation: Braz J Microbiol. 2012 Apr;43(2):786-92
references.pmid: 24031891
references.citation: PLoS Genet. 2012;8(12):e1003065
references.pmid: 23236287
references.citation: Molecules. 2011;16(9):7958-68
references.pmid: 21921868
references.citation: Eur J Pharmacol. 2013 Aug 15;714(1-3):163-9
references.pmid: 23792140
references.citation: Int J Cancer. 2007 Oct 1;121(7):1424-32
references.pmid: 17551921
references.citation: Leukemia. 2003 Sep;17(9):1794-805
references.pmid: 12970779
references.citation: Food Chem Toxicol. 2012 Sep;50(9):3306-12
references.pmid: 22705327
references.citation: Asian Pac J Cancer Prev. 2012;13(9):4699-701
references.pmid: 23167405
references.citation: Trop Biomed. 2011 Dec;28(3):589-98
references.pmid: 22433888
references.citation: Phytomedicine. 2011 Dec 15;19(1):56-63
references.pmid: 21924600
references.citation: Mod Pathol. 2009 Apr;22(4):522-9
references.pmid: 19234438
references.citation: J Agric Food Chem. 2013 Oct 16;61(41):9839-48
references.pmid: 24059278
references.citation: Int J Cancer. 2010 Sep 1;127(5):1081-95
references.pmid: 20027628